| Vaccine description | |
|---|---|
| Target | melanoma, renal cancer |
| Vaccine type | Conjugate |
| Clinical data | |
| Trade names | HybriCell |
| Identifiers | |
| ChemSpider |
|
HybriCell is a therapeutic vaccine developed by Brazilian immunologist Jose Alexandre Barbuto. The treatment, which inhibits the division of cancer cells, is aimed at patients in later stages of kidney cancer or melanoma. The vaccine works by extracting certain leukocytes from the patient's blood and merging them with cancer cells, enabling the body to recognize and attack other similar cancer cells.[unreliable medical source?][1] In studies conducted in 2001 and 2003, 80% of test subjects showed improvement without harmful side effects.[unreliable medical source?][2] Though test groups were relatively small, the results of the studies show evidence that the drug is effective.[unreliable medical source?][3]
- ^ [unreliable medical source?] "HybriCell - Vacina Contra o Cancer" (in Portuguese). Florida Brasil. 2005-08-08. Retrieved 2012-03-02.
- ^ [unreliable medical source?] "Brazilian Scientist creates one of the first commercially available vaccine against cancer in the world". Genoa Biotechnologia. Archived from the original on 2012-12-31. Retrieved 2012-01-02.
- ^ [unreliable medical source?] Brambilla A (2005-05-09). "Brazilian Doctor Unveils Cancer Vaccine". OhMy News. Archived from the original on 2008-03-20. Retrieved 2012-03-02.